Pediatr Nephrol (2008) 23:717–725 39. Madersbacher H, Jilg G (1991) Control of detrusor hyperreflexia by the intravesical instillation of oxybutynin hydrochloride. Paraplegia 29:84–90 40. Buyse G, Verpoorten C, Vereecken R, Casaer P (1995) Treatment of neurogenic bladder dysfunction in infants and children with neurospinal dysraphism with clean intermittent (self) catheter- isation and optimized intravesical oxybutynin hydrochloride therapy. Eur J Pediatr Surg 5:31–34 41. Buyse G, Verpoorten C, Vereecken R, Casaer P (1998) Intra- vesical application of a stable oxybutynin solution improves therapeutic compliance and acceptance in children with neuro- genic bladder dysfunction. J Urol 160:1084–1087 42. Amark P, Bussman G, Eksborg S (1998) Follow-up of long-time treatment with intravesical oxybutynin for neurogenic bladder in children. Eur Urol 34:148–153 43. Haferkamp A, Staehler G, Gerner HJ, Dörsam J (2000) Dosage escalation of intravesical oxybutynin in the treatment of neuro- genic bladder patients. Spinal Cord 38:250–254 44. Fratta A, Bordenave J, Boissinot C, Le Grand J, Esquirol C, Radideau E, Benoit G (2005) Development of an intravesical oxybutynin chloride solution: from formulation to quality control. Ann Pharm Fr 63:162–166 45. Buyse G, Waldeck K, Verpoorten C, Björk H, Casaer P, Andersson KE (1998) Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism. J Urol 160:892–896 46. De Wachter S, Wyndaele JJ (2003) Intravesical oxybutynin: a local anesthetic effect on bladder C afferents. J Urol 169:1892– 1895 47. Kim Y, Yoshimura N, Masuda H, de Miguel F, Chancellor MB (2005) Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder afferent pathways. Urology 65:238–242 48. Youdim K, Kogan BA (2002) Preliminary study of the safety and efficacy of extended-release oxybutynin in children. Urology 59:428–432 49. Goessl C, Sauter T, Michael T, Bergé B, Staehler M, Miller K (2000) Efficacy and tolerability of tolterodine in children with detrusor hyperreflexia. Urology 55:414–418 725 50. Reitz A, Stöhrer M, Kramer G, Del Popolo G, Chartier-Kastler E, Pannek J, Burgdörfer H, Göcking K, Madersbacher H, Schumacher S, Richter R, von Tobel J, Schurch B (2004) European experience of 200 cases treated with Botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45:510–515 51. Altaweel W, Jednack R, Bilodeau C, Corcos J (2006) Repeated intradetrusor botulinum toxin type A in children with neurogenic bladder due to myelomeningocele. J Urol 175:1102–1105 52. Kasabian NG, Bauer SB, Dyro FM, Colodny AH, Mandell J, Retik AB (1992) The prophylactic value of clean intermittent catheterization and anticholinergic medication in newborns and infants with myelodysplasia at risk of developing urinary tract deterioration. Am J Dis Child 146:840–843 53. Madersbacher H (2002) Neurogenic bladder dysfunction in patients with myelomeningocele. Curr Opin Urol 12:469–472 54. Berger R, Maizels M, Moran G, Conway J, Firlit C (1983) Bladder capacity (ounces) equals age (years) plus 2 predicts normal bladder capacity and aids in diagnosis of abnormal voiding patterns. J Urol 129:347–349 55. Houle AM, Gilmour RF, Churchill BM, Gaumond M, Bissonnette B (1993) What volume can a child normally store in the bladder at a safe pressure? J Urol 149:561–564 56. Liptak GS (2003) Evidence-based practice in spina bifida: developing a research agenda, May 9–10, 2003, Washington DC AAnnsswweerrss 1. c 1. c 22. .bb 33. .bb 44. .aa 55. .cc